Monopar Therapeutics presented new data at AASLD showing that ALXN1840 (tiomolybdate choline) rapidly improved copper balance in Wilson disease patients through increased fecal copper excretion.

Monopar Therapeutics is conducting a $135 million underwritten offering of common stock and pre-funded warrants, with plans to use proceeds for general corporate purposes and a stock repurchase from Tactic Pharma.

Monopar Therapeutics published a Letter to the Editor in the Journal of Hepatology, reanalyzing their Phase 2 ALXN1840-WD-204 study for Wilson disease. The new analysis shows that ALXN1840 statistically significantly improved copper balance by accounting for additional routes of copper loss.

Monopar Therapeutics has in-licensed ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease. The company also has two novel radiopharma clinical trials active and enrolling patients with advanced solid cancers.

Monopar Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $19.2 million public offering of its common stock at $16.25 per share. The proceeds will be used for general corporate purposes, including research and development, clinical trials, and working capital.

WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors” has been accepted as a “Top-Rated Oral Presentation” within the Scientific Program of the European Association of Nuclear Medicine (EANM) 2024 Annual Congress to be held on October 19-23, 2024 in Hamburg, Germany.

Highlights:

WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar’s Chief Financial Officer, Kim R. Tsuchimoto, will be retiring.

After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Initiated MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial

WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in Toronto, Canada, is recognized as the premier educational, scientific, and research event in the radiopharma space.

WILMETTE, Ill., April 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) is now active and recruiting patients with advanced cancers. The antibody MNPR-101 targets the urokinase plasminogen activator receptor (uPAR), which is expressed on numerous tumor types including pancreatic, breast, colorectal, and bladder.